Feasibility of quantifying change in immune white cells in abdominal adipose tissue in response to an immune modulator in clinical obesity.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
01
2020
accepted:
27
07
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Obesity is often associated with inflammation in adipose tissue (AT) with release of mediators of atherogenesis. We postulated that it would be feasible to collect sufficient abdominal AT to quantify changes in a broad array of adaptive and innate mononuclear white cells in obese non-diabetic adults in response to a dipeptidyl protease inhibitor (DPP4i), known to inhibit activation of immune white cells. Adults 18-55 years-of-age were screened for abdominal obesity and insulin resistance or impaired glucose tolerance but without known inflammatory conditions. Twenty-one eligible participants consented for study and were randomized 3:1 to receive sitagliptin (DPP4i) at 100mg or matching placebo daily for 28 days. Abdominal AT collected by percutaneous biopsy and peripheral blood mononuclear cell fractions were evaluated before and after treatment; plasma was stored for batch testing. Highly sensitive C-reactive protein, a global marker of inflammation, was not elevated in the study population. Innate lymphoid cells (ILC) type 3 (ILC-3) in abdominal AT decreased with active treatment compared with placebo (p = 0.04). Other immune white cells in AT and peripheral blood mononuclear cell (PBMC) fractions did not change with treatment compared to placebo (p>0.05); although ILC-2 declined in PBMCs (p = 0.007) in the sitagliptin treatment group. Two circulating biomarkers of atherogenesis, interferon-inducible protein-10 (IP-10) and sCD40L declined in plasma (p = 0.02 and p = 0.07, respectively) in the active treatment group, providing indirect validation of a net reduction in inflammation. In this pilot study, two cell types of the innate lymphoid system, ILC-3 in AT and ILC-2 PBMCs declined during treatment and as did circulating biomarkers of atherogenesis. Changes in other immune cells were not demonstrable. The study showed that sufficient abdominal AT could be obtained to quantify white cells of both innate and adaptive immunity and to demonstrate changes during therapy with an immune inhibitor. ClinicalTrials.gov identifier (NCT number): NCT02576.
Sections du résumé
BACKGROUND
Obesity is often associated with inflammation in adipose tissue (AT) with release of mediators of atherogenesis. We postulated that it would be feasible to collect sufficient abdominal AT to quantify changes in a broad array of adaptive and innate mononuclear white cells in obese non-diabetic adults in response to a dipeptidyl protease inhibitor (DPP4i), known to inhibit activation of immune white cells.
METHODS
Adults 18-55 years-of-age were screened for abdominal obesity and insulin resistance or impaired glucose tolerance but without known inflammatory conditions. Twenty-one eligible participants consented for study and were randomized 3:1 to receive sitagliptin (DPP4i) at 100mg or matching placebo daily for 28 days. Abdominal AT collected by percutaneous biopsy and peripheral blood mononuclear cell fractions were evaluated before and after treatment; plasma was stored for batch testing.
RESULTS
Highly sensitive C-reactive protein, a global marker of inflammation, was not elevated in the study population. Innate lymphoid cells (ILC) type 3 (ILC-3) in abdominal AT decreased with active treatment compared with placebo (p = 0.04). Other immune white cells in AT and peripheral blood mononuclear cell (PBMC) fractions did not change with treatment compared to placebo (p>0.05); although ILC-2 declined in PBMCs (p = 0.007) in the sitagliptin treatment group. Two circulating biomarkers of atherogenesis, interferon-inducible protein-10 (IP-10) and sCD40L declined in plasma (p = 0.02 and p = 0.07, respectively) in the active treatment group, providing indirect validation of a net reduction in inflammation.
CONCLUSIONS
In this pilot study, two cell types of the innate lymphoid system, ILC-3 in AT and ILC-2 PBMCs declined during treatment and as did circulating biomarkers of atherogenesis. Changes in other immune cells were not demonstrable. The study showed that sufficient abdominal AT could be obtained to quantify white cells of both innate and adaptive immunity and to demonstrate changes during therapy with an immune inhibitor.
TRIAL REGISTRATION
ClinicalTrials.gov identifier (NCT number): NCT02576.
Identifiants
pubmed: 32881912
doi: 10.1371/journal.pone.0237496
pii: PONE-D-19-34204
pmc: PMC7470412
doi:
Substances chimiques
Biomarkers
0
Sitagliptin Phosphate
TS63EW8X6F
Banques de données
ClinicalTrials.gov
['NCT00002576']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0237496Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL144790
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001855
Pays : United States
Déclaration de conflit d'intérêts
None of the authors have competing interests.
Références
J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9
pubmed: 16912128
Am J Clin Nutr. 1996 Nov;64(5):685-93
pubmed: 8901786
Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1654-9
pubmed: 18566296
Circ J. 2003 Oct;67(10):851-4
pubmed: 14578618
Nat Med. 2015 Jul;21(7):698-708
pubmed: 26121198
Nature. 2014 Oct 9;514(7521):237-41
pubmed: 25119041
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
Lancet. 2005 Apr 9-15;365(9467):1348-53
pubmed: 15823387
J Am Coll Cardiol. 2012 Jan 17;59(3):265-76
pubmed: 22240132
Metabolism. 2006 Feb;55(2):237-42
pubmed: 16423632
Immunity. 2016 Aug 16;45(2):428-41
pubmed: 27496734
Biomed Res Int. 2014;2014:893106
pubmed: 24868552
Nature. 1985 Jun 20-26;315(6021):672-6
pubmed: 3925348
Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2251-60
pubmed: 21817098
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
J Exp Med. 2006 Jul 10;203(7):1693-700
pubmed: 16818676
J Exp Med. 2013 Mar 11;210(3):535-49
pubmed: 23420878
Clin Sci (Lond). 2016 Apr 1;130(7):463-78
pubmed: 26888559
Circulation. 2001 Nov 6;104(19):2266-8
pubmed: 11696462
J Clin Invest. 2007 Jan;117(1):175-84
pubmed: 17200717
J Immunol Methods. 2012 Dec 14;386(1-2):50-9
pubmed: 22974837
Ann N Y Acad Sci. 2001 Dec;947:329-36
pubmed: 11795284
J Allergy Clin Immunol. 2016 Jul;138(1):305-308
pubmed: 26949057
Immunity. 2015 Mar 17;42(3):538-51
pubmed: 25769613
Cell Immunol. 2017 May;315:18-26
pubmed: 28285710
Immunity. 2014 Sep 18;41(3):366-374
pubmed: 25238094
Int J Obes (Lond). 2015 Jan;39(1):183-6
pubmed: 24849392
Sci Rep. 2017 Jun 14;7(1):3501
pubmed: 28615725
PLoS One. 2015 Oct 27;10(10):e0141394
pubmed: 26506526
J Clin Endocrinol Metab. 2012 Sep;97(9):3333-41
pubmed: 22745245
Circ Res. 2001 Dec 7;89(12):1092-103
pubmed: 11739273
Metabolism. 2013 Mar;62(3):347-51
pubmed: 23062489
Obes Res. 1994 Nov;2(6):563-8
pubmed: 16355516
Cytokine Growth Factor Rev. 1997 Sep;8(3):207-19
pubmed: 9462486
J Cardiovasc Transl Res. 2016 Aug;9(4):302-14
pubmed: 27271043
Nutr Res Rev. 1993 Jan;6(1):137-59
pubmed: 19094306
Atherosclerosis. 1998 Apr;137 Suppl:S89-95
pubmed: 9694547
J Am Coll Cardiol. 2011 Jul 12;58(3):232-7
pubmed: 21737012
Nat Med. 2012 Mar 06;18(3):363-74
pubmed: 22395709
Clin Endocrinol (Oxf). 2010 Aug;73(2):189-96
pubmed: 20039889
Nature. 2015 Mar 12;519(7542):242-6
pubmed: 25533952
J Gen Virol. 1989 Oct;70 ( Pt 10):2661-72
pubmed: 2677236
Blood. 2003 Jun 1;101(11):4452-6
pubmed: 12531788
Nat Commun. 2019 Feb 12;10(1):713
pubmed: 30755607
Metabolism. 2012 Aug;61(8):1152-61
pubmed: 22386937
J Clin Endocrinol Metab. 2015 Jul;100(7):2621-9
pubmed: 25938633
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
J Exp Med. 2006 Jul 10;203(7):1701-11
pubmed: 16818678
Obesity (Silver Spring). 2016 Jun;24(6):1274-82
pubmed: 27133873
Nature. 1998 Jul 9;394(6689):200-3
pubmed: 9671306
Diabetes. 2011 Nov;60(11):2802-9
pubmed: 22025778
Nat Med. 2014 Dec;20(12):1417-26
pubmed: 25362253
Diabetes. 2006 Mar;55(3):774-9
pubmed: 16505242
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):194-9
pubmed: 16239601
Nat Immunol. 2012 Oct;13(10):947-53
pubmed: 22922363